Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Established in 1972 and headquartered in Paris, with additional offices in London and Milan, the firm has supported the growth of over 500 companies over its 50-year history.
Sofinnova Partners invests across the entire life sciences value chain, from seed to later-stage companies. Their investment strategies encompass early-stage biopharma and medtech startups focusing on groundbreaking therapeutic technologies, as well as later-stage growth opportunities in biotech and medtech companies.
In March 2025, Sofinnova Partners announced that it had raised €1.2 billion across its platform of investment strategies over the past year, including more than €1 billion secured in the last quarter. This achievement brings the firm's AUM to more than €4 billion, solidifying its position as a leading backer of transformative innovation in healthcare and sustainability.
And another new biotechnology-focused fund, raising €165 million euros, or more than $180 million, to help young drugmakers advance new medicines.
Leadership
Sofinnova Partners is led by an experienced team of professionals with deep sector expertise. Antoine Papiernik serves as the Chairman and Managing Partner. The firm comprises over 80 professionals, including 25 investment partners, spanning 24 nationalities across its three European offices.
Investment Strategy
The firm's investment strategy involves acting as a founding and lead investor in early-stage biopharma and medtech startups focusing on groundbreaking therapeutic technologies. They actively partner with ambitious entrepreneurs to develop transformative innovations that have the potential to positively impact our collective future.
Notable Investments
Sofinnova Partners has invested in several innovative companies, including:
Notable Exits
Over the last decade, Sofinnova Partners has completed nine remarkable exits in its portfolio for a total enterprise value of almost €4 billion.
